文献速递类风湿关节炎其他结缔组织病

β2糖蛋白I IgA抗体可预测类风湿关节炎患者冠状动脉斑块进展

Beta-2-glycoprotein-I IgA antibodies predict coronary plaque progression in rheumatoid arthritis.
PubMed 文献 · Semin Arthritis Rheum · 2020-12-17

结果显示抗β2GPI IgA抗体虽与基线斑块负荷无关,但与斑块进展、新发广泛或阻塞性斑块及混合斑块形成相关,并改善风险预测模型的判别能力。

要点

  • 抗β2GPI IgA阳性者随访期间节段受累评分增加风险升高(调整RR=1.64)。
  • 抗β2GPI IgA阳性者新发广泛或阻塞性斑块风险显著升高(调整OR=4.24)。
  • 抗β2GPI IgA可修饰炎症对CAC变化及CVD事件的影响。

核心结论

  • 抗β2GPI IgA加入临床风险模型可提高对CAC变化、斑块进展及向广泛/阻塞性病变转变的预测准确性。

主要发现

  • 抗β2GPI IgA见于45例(30%)患者,与基线斑块负荷无关联。
  • 抗β2GPI IgA与节段受累评分增加相关(调整RR=1.64,95%CI 1.02-2.63)。
  • 抗β2GPI IgA与CAC变化相关(调整β=0.33,95%CI 0.002-0.656)。
  • 抗β2GPI IgA与新发广泛或阻塞性斑块相关(调整OR=4.24,95%CI 1.30-13.87)。
  • 在节段分析中,抗β2GPI IgA预测混合斑块形成(调整OR=3.20,95%CI 1.01-10.09),并降低混合斑块向钙化斑块转变的可能性(调整OR=0.19,95%CI 0.04-0.96)。

关键数值与推荐

  • 将抗β2GPI IgA加入含传统危险因素的logistic回归模型后,预测斑块进展结局的AUC增加,NRI和IDI改善(均P<0.05)。
  • 仅在抗β2GPI IgA阳性患者中,CRP与CAC变化相关(β=0.26,95%CI 0.14-0.38),且与CVD风险相关(调整HR=1.89,95%CI 1.02-3.51)。

临床怎么用

  • 在类风湿关节炎患者中可考虑检测抗β2GPI IgA以辅助评估冠状动脉斑块进展和CVD风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate whether anti-Beta-2-Glycoprotein-I (anti-β2GPI) IgA antibodies associate with progression of coronary atherosclerosis and cardiovascular disease (CVD) events in rheumatoid arthritis (RA). METHODS: One hundred-fifty patients underwent plaque evaluation (total, non-calcified, mixed and calcified) with coronary computed tomography angiography; 101 were re-imaged within 6.9±0.3 years to assess progression. The Framingham-D'Agostino score assessed cardiovascular risk. Coronary artery calcium (CAC) and segment involvement score quantified plaque burden. RESULTS: Anti-β2GPI IgA were seen in 45 (30%) patients. Despite no link to baseline plaque burden, anti-β2GPI IgA associated with segment involvement score increase (adjusted-RR=1.64 [95%CI 1.02-2.63]), CAC change (adjusted-β=0.33 [95%CI 0.002-0.656]) and developing new extensive or obstructive plaque at follow-up (adjusted-OR=4.24 [95%CI 1.30-13.87]). Adding anti-β2GPI IgA to logistic regression models with conventional risk factors predicting plaque progression outcomes increased Area under the receiver-operator curve and improved Net Reclassification and Integrated Discrimination Improvement indices (all P<0.05). In per-segment analyses, anti-β2GPI IgA predicted mixed plaque formation (adjusted-OR=3.20 [95%CI 1.01-10.09]) and lower likelihood of transition of mixed to calcified plaque (adjusted-OR=0.19 [95%CI 0.04-0.96]). Anti-β2GPI IgA moderated the effect of C-reactive protein on CAC change such that C-reactive protein associated with CAC change (β=0.26 [95%CI 0.14-0.38]) and CVD risk (adjusted-HR=1.89 [95%CI 1.02-3.51]) only in anti-β2GPI IgA positive patients. CONCLUSION: Anti-β2GPI IgA addition to clinical risk models improved prediction accuracy of CAC, plaque progression and transition to extensive/obstructive disease. They associated with new high-risk mixed plaques and delayed healing to calcified lesions. Anti-β2GPI IgA further modified the effect of inflammation on plaque progression and CVD events.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Karpouzas GA, Ormseth SR, Hernandez E, et al. Beta-2-glycoprotein-I IgA antibodies predict coronary plaque progression in rheumatoid arthritis. Semin Arthritis Rheum. 2020. PMID: 33360226. doi:10.1016/j.semarthrit.2020.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。